Royal Bank of Canada
WX

Royal Bank of Canada’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Royal Bank of Canada’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-203,472
Closed -$8.79M – 7151
2015
Q3 		$8.79M Buy
203,472
+16,285
+9% +$687K 0.01% 1236
2015
Q2 		$7.91M Buy
187,187
+10,497
+6% +$443K 0.01% 1326
2015
Q1 		$6.85M Buy
176,690
+16,577
+10% +$638K ﹤0.01% 1406
2014
Q4 		$5.39M Buy
160,113
+16,824
+12% +$594K ﹤0.01% 1631
2014
Q3 		$5.02M Buy
143,289
+50,320
+54% +$1.72M ﹤0.01% 1654
2014
Q2 		$3.06M Buy
92,969
+40,806
+78% +$1.4M ﹤0.01% 1993
2014
Q1 		$1.92M Sell
52,163
-3,688
-7% -$135K ﹤0.01% 2273
2013
Q4 		$2.15M Buy
55,851
+7,551
+16% +$238K ﹤0.01% 2263
2013
Q3 		$1.32M Sell
48,300
-100
-0.2% -$2.37K ﹤0.01% 2516
2013
Q2 		$1.02M Buy
+48,400
New +$945K ﹤0.01% 2561

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Royal Bank of Canada's WX Position: Q4 2015 in Review

Royal Bank of Canada sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 203,472 shares — an estimated $8.79M sold.

Royal Bank of Canada first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $8.79M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Royal Bank of Canada reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Royal Bank of Canada sold 203,472 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $8.79M.
  • Royal Bank of Canada first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Royal Bank of Canada's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $8.79M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Royal Bank of Canada's 13F filing for Q4 2015, filed 16 Feb 2016.